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Abstract
Background: In Luxembourg, viral hepatitis and HIV infection data in problem drug users (PDUs) are primarily
based on self-reporting. Our study aimed to determine the prevalence of HAV, HBV, HCV and HIV infections in ever
injecting (IDUs) and non-injecting drug users (nIDUs) including inherent risk factors analysis for IDUs. Secondary
objectives were immunisation against HAV and HBV, referral to care and treatment facilities as well as reduction in
risk behaviour.
Methods: A nationwide, cross-sectional multi-site survey, involving 5 in-, 8 out-treatment and 2 prison centres,
included both an assisted questionnaire (n = 368) and serological detection of HIV and Hepatitis A, B, C (n = 334).
A response rate of 31% resulted in the participation of 310 IDUs and 58 nIDUs.
Risk factors such as drug use, sexual behaviour, imprisonment, protection and health knowledge (HAV, HBV status
and immunisations, HCV, HIV), piercing/tattoo and use of social and medical services were studied by means of
chi2 and logistic models.
Results: Seroprevalence results for IDUs were 81.3% (218/268, 95%CI=[76.6; 86.0]) for HCV, 29.1% (74/254, 95%CI=
[25.5;34.7 ]) for HBV (acute/chronic infection or past cured infection), 2.5% (5/202, 95%CI=[0.3; 4.6]) for HIV-1 and
57.1% (108/189, 95%CI=[50.0; 64.1]) for HAV (cured infections or past vaccinations). Seroprevalence results for nIDUs
were 19.1% (9/47, 95%CI=[7.9;30.3]) for HCV, 8.9% (4/45, 95%CI=[0.6;17.2]) for HBV (acute/chronic infection or past
cured infection), 4.8% (2/42, 95%CI=[-1.7;11.3]) for HIV-1 and 65.9% (27/41, 95%CI=[51.4;80.4]) for HAV. Prisoners
showed the highest rates for all infections. Age, imprisonment and setting of recruitment were statistically
associated with HCV seropositivity. Age, speedball career and nationality were significantly associated with HBV
seropositivity. Only 56% of the participants in outpatient centres collected their serology results and 43 doses of
vaccine against HAV and/or HBV were administered.
Conclusions: Despite the existing national risk-reduction strategies implemented since 1993, high prevalence of
HCV and HBV infections in injecting drug users is observed. Our study showed that implementing risk-prevention
strategies, including immunisation remains difficult with PDUs. Improvement should be looked for by the provision
of field healthcare structures providing tests with immediate results, advice, immunisation or treatment if
appropriate.
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The prevalence of hepatitis C virus (HCV) infection in
injecting drug users varies between regions in Europe
from 40 to 90% [1]. Before 2005, data on the prevalence
of hepatitis B virus (HBV) infection in IDUs were lim-
ited. Prevalence figures for Europe in 2007-08 [2] were
highly variable due to differences in vaccination cover-
age. The positivity of the Hepatitis core antibody (anti-
HBc) which indicates a contact with the viral particle
reveals a hepatitis B prevalence over 40%. Limited preva-
lence data exist for hepatitis A (HAV) infection in the
same population. Human immunodeficiency virus type 1
(HIV-1) prevalence in IDUs ranges between 0% and 21%
in the European Union, although it does not exceed 5%
in most Member states [3].
Prevalence of HCV among nIDUs varies in Europe
between 10 and 20% [4] and remains higher than
among the general population. The same prevalence
trend is observed among nIDUs for HBV and HIV
infections [4-6].
Epidemiological follow-up of problem drug use in
Luxembourg relies on a nation-wide multi-sector sur-
veillance system called “RELIS”. RELIS was established
in 1995 and conceived on the methodological assump-
tion that data exclusively collected from drug treatment
settings may not provide an accurate picture of the pro-
blem drug-using population as it notably excludes out-
of-treatment drug users who for instance have had con-
flicts with law enforcement bodies due to the proble-
matic aspect of their drug use. The RELIS network
includes in- and out-patient treatment centres (100%
coverage), including hospitals providing detoxification
treatment, national prisons and law enforcement agen-
cies. Data collection is performed via a series of contex-
tual protocols ("first contact”, “update” or
“identification” protocol), self-reported data and setting-
related data (number of: contacts, syringes exchanged...).
The yearly output of RELIS largely contributes to the
publication of the national annual drugs report. Accord-
ing to RELIS data [3] a weak upward trend in HIV/
IDUs self-reported prevalence has been observed from
3.5% in 1998 to 5% in 2004, and hepatitis C prevalence
stood at 74% in 2004. In 1998, the first published data
about Luxembourg prison [7] reported HIV and HCV
prevalence in IDU prison inmates of 4.3%, respectively
37%. Among all reported new cases of HIV-1 infection
in Luxembourg, few seem to occur in IDUs [4]: 6 HIV-1
infections out of 30 new cases (20%) occurred through
injecting drug use in 1999 compared to only 3 out of 60
(5%) in 2004 [8].
Our study pursued three goals: i) defining the preva-
lence of viral hepatitis B, C and HIV in IDUs and
nIDUs in Luxembourg, ii) analysing risk factors of viral
infections in IDUs and iii) assessing the need and feasi-
bility of HAV and HBV immunisations in PDUs.
Methods
Settings and participants
To approach the genuine heterogeneity of the drug mis-
use phenomenon, RELIS routinely compiles data from
law enforcement agencies, the 2 prisons, inpatient (spe-
cialised or psychiatric hospital wards: 6) or outpatient
(substitution treatment programmes, low-threshold facil-
ities, drop-in centres for sex workers, drug consultation
centres: 8) centres providing counselling, assistance and
drug treatment to PDUs throughout the country. Also,
the national drug surveillance system relies on the con-
cept of the ‘institutional contact indicator’, as an alterna-
tive to the better-known treatment demand indicator
[9]. Furthermore, the case definition applied by RELIS,
detailed below, refers to PDUs and is not limited to
IDUs, heroin users or opiate users - even though the
RELIS database allows extracting data on these sub-
groups.
According to the RELIS case definition, a problem
user of illicitly acquired drugs (referred to as PDU) is
defined as a person who shows a) current and regular
use of opiates, cocaine, and/or amphetamines, and b)
current contact with a health or law enforcement insti-
tution due to the use of listed drugs. Route of adminis-
tration is not considered as a selection criteria. The use
of other licit or illicit substances whether prescribed or
not, is not an exclusion criteria as long as it is asso-
ciated with the described drug use pattern.
The latest PDU prevalence study prior to the present
research reported an absolute prevalence of 2530 PDUs
among the national population aged 15 to 64 years [7].
To reach representativeness of the PDUs population in
Luxembourg, a sample of 400 respondents (15-16%) was
projected, aiming for similar rates of recruitment in all
participating sites. The study sites included inpatient
(ITC) and outpatient (OTC) treatment centres and pris-
ons (PC) in Luxembourg. ITCs are centres where PDUs
h a v es p e n ta tl e a s to n en i g h t( e . gh o s p i t a l s ) .O T C sa r e
settings where ambulant PDUs and sex workers can
have easy and free access to drug substitution, psycholo-
gical or medical advice, as well as services such as
exchange programmes or social counselling. Basic physi-
cal and psychological needs are also addressed in such
settings.
Among the 16 eligible sites (2 PC, 8 OTC, and 6 ITC)
and leaving aside law enforcement agencies and one
outpatient centre for minors only, the study sites
included all the RELIS network centres with the excep-
tion of one hospital. This allowed reaching remarkable
national service representativeness.
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eligible for inclusion in the study when reporting use of
opiates, cocaine, amphetamines or being under medical
substitution (methadone, buprenorphine...) irrespective
of the route of administration and duration of use. IDUs
are defined as having injected at least once in lifetime.
The study was designed as a “research-action”, offer-
ing participants free medical counselling, risk-reduction
material and immunisation against HAV and HBV. The
study was performed according to the Declaration of
Helsinki and approved by the National Research Ethics
Committee and the National Commission for Data Pro-
tection (NCDP).
Questionnaire
The trained field investigator informed each participant
on the study before proceeding to an assisted question-
naire and a prevention message with handover of risk
reduction material. A personal identification code
(RELIS code) approved by the NCDP, was computed
from gender, date and country of birth variables.
Written informed consent was obtained for all inter-
views, blood sampling or medical file consultation. Each
stage of participation gave right to a free meal voucher
for the participants. Multiple strategies were used to
facilitate recruitment such as flyer distribution (central
railway station, pharmacies...) and direct approaching of
PDUs by street workers.
The questionnaire was based on a “Scottish question-
naire” [10] and the EU consensus questionnaire
designed by the European Monitoring Centre for Drug
and Drug Addictions (Van Ameijden E, Wiessing L:
Consensus questionnaire for Young Problematic Drug
Users. Lisbon EMCDDA meeting 2000 jun 15-16.
Unpublished reports.) focusing on socio-demographic
information, drug use, injecting behaviour, sexual beha-
viour, imprisonment, protection and health knowledge
(HAV, HBV status and immunisations, HCV, HIV),
piercing/tattoo and use of social and medical services.
This questionnaire was made available in French, Ger-
man and Portuguese after a validated translation proce-
dure. On average, it took 30 minutes to be completed.
Blood sampling
In ITCs and PCs, serology results and immunisation fol-
low-ups were gathered from medical files. In OTCs,
PDUs were offered blood sampling for HIV and hepati-
tis serology. During the 8-month recruitment period
and for an additional 6 months after the inclusion of the
last respondent, results and, if needed, immunisations
were given at the same location by a physician. Blood
samples collected on site were transported to the labora-
tory on the same day. Serum specimens were aliquoted
and stored at -20°C until the ELISA serology tests were
performed on an automated Abbott AXSYM System
(Abbott, Brussels, Belgium). The following tests were
performed: for HAV, IgG (HAVAB 2.0 Reagents) and
IgM antibodies (HAVAB.M 2.0 Reagents), for HBV, HBs
antigen, anti-HBs antibodies (AUSAB reagents), anti-
HBc antibodies (CORE reagents), for HCV, anti-HCV
antibodies (HCV 3.0 reagents), and for HIV-1 and 2
(HIV Ag/Ab Combo Reagents). In case of a positive
ELISA test for HCV or HIV, confirmation tests were
manually performed (for HCV, CHIRON RIBA HCV 3.0
SIA (Ortho Clinical Diagnostics, Raviatan, New Jersey,
USA) and for HIV, HIV BLOT 2.2 (Genelabs Diagnos-
tics, Singapore, Singapore) and Vironostika HIV-1 Anti-
gen (Biomerieux, Boxtell, The Netherlands)).
Immunisations
When appropriate, immunisations against HAV and
HBV with Havrix 1440, Engerix B20, or Twinrix Adult
(GlaxoSmithKline, Rixensart, Belgium) were offered free
of charge in OTC. Immunisations were provided routi-
nely - independently of the present study - in ITC and
PC.
Statistical analysis
The use of the RELIS code coupled with a single field
investigator allowed avoiding duplicates in the process
of data management. Student T-tests compared continu-
ous variables, Chi-square or Fisher’se x a c tt e s t sw h e r e
appropriate compared categorical variables. Odds ratio
and their Confidence Intervals (95%CI) were calculated
when possible. For both HCV and HBV, logistic regres-
s i o nw a sa p p l i e db yu s i n gas t e p w i s em a n u a lb a c k w a r d
approach to select probable risk factors (that were sig-
nificant at a p-value below 0.20 in descriptive analysis)
where a non-significant likelihood ratio test was found.
The final model was also adjusted for known covariates
(age).
A p-value below 0.05 was considered statistically sig-
nificant. All tests were two-tailed. Analyses were carried
out with SPSS Statistical software version 13 (SPSS Inc.
Chicago, IL, USA) and SAS System version 9.2 (SAS
Institute, Cary, NC, USA).
Results
Description of the study population
From January 1 to August 31, 2005, 1,169 contacts were
made with PDUs (Figure 1). The main causes of partici-
pation refusal was “lack of interest” in the study (N =
525) and some participants refused to participate simply
by postponing questionnaire completion without show-
ing up again (N = 247). Tests on internal consistency
rejected 6 questionnaires for contradictory answers, 10
blood-screening samples yielded insufficient amounts of
blood and 28 serologies were excluded because not
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results from ITC and PC were included in the analysis
only if obtained between January 1, 2005 and August 31,
2005, unless they had already been positive for HAV,
HBV, HCV or HIV before January 2005. Finally, 368
inclusions were accepted (participation rate: 31%), repre-
senting about 14.5% of the estimated RELIS 2005 [11]
total PDU population in Luxembourg, of whom all
Never IDUs
N=45
Total serologies (valid) N=334 Completed questionnaires 
(valid) N=368
IDUs
N=310
nIDUs
N=58
Rejected questionnaires N=6
Contacts not conclusive 
Judged “lack of interest” N=525
Reporting the “meeting date” N=247
Total Contacts 
N=1169
Completed questionnaires (with or without associated blood 
sample or medical file serology) N=374
Blood samples (OTC)
(with or without associated questionnaire)
N=169
HBV N=299 HCV N=315 HIV N=244
IDUs
N=254
IDUs
N=268
nIDUs
N=42
nIDUs
N=47
IDUs
N=202
OTC
N=148
ITC
N=79
PC
N=141
OTC
N=131
ITC
N=68
PC
N=134
Vaccination needed N=78
Retrieved results
N=73
Unretrieved results
N=58
55%
One dose of vaccine administrated 
N=43
Entries in the Data base* N=397
Total serologies (valid) N=362
Rejected serologies: not associated to completed questionnaire 
N=28
nIDU
N=45
Rejected blood samples (OTC):
Insufficient blood N=10
Associated to uncompleted questionnaire N=28
Figure 1 Study Flow Chart. * Respondents could either do both the questionnaire and the screening/give access to their serology or just one
of these two.
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results.
Participation rate of PDUs in the questionnaire-based
interviews was lower in OTCs (148/176; 84%) than in
ITCs (79/79; 100%) and PCs (141/142; 99%) but no dif-
ference in the distribution of IDUs and nIDUs (non-
IDUs) between the 3 settings (OTC 119/148, ITC 69/79,
PC 122/141, p = 0.25) was observed. 84% (310/368, 95%
CI=[80.2; 87.7]) of respondents were IDUs and 16%
nIDUs, constituting the studied population whose main
characteristics are displayed in Table 1. Men were sig-
nificantly (p = 0.035) older (mean +/- SD: 31 +/- 7.9
years) than women (29 +/- 6.4) in IDUs and nIDUS
(men 29 +/- 7.5 vs women 24 +/- 8.7, p = 0.029).
Women in IDUs were older (29 +/- 6.4) than among
nIDUs (24 +/-8.7) (p = 0.021).
Among IDUs the average number of years elapsed
since the first use of injectable drug (cocaine, heroin,
speedball, amphetamines) was 10.0 years (SD: 7.5). From
the IDUs having injected in the last 6 months, 75% of
the sterile syringes were obtained through syringe
exchange programs and 12% from pharmacies. Sixty-five
percent gave back their used syringes at a syringe
exchange program point, although 15% of these syringes
w e r es e p a r a t e df r o mt h e i rn e e d l ea n d8 %o ft h en e e d l e s
were discarded in an inappropriate location (e.g. dustbin
or street).
In prisons, 75 in 122 IDUs (55%) injected drugs dur-
ing their detainment. Forty of them (53%) reused their
own syringes and needles which had never been shared
with another person. Among the 60 IDUs who reused
their syringes whether shared or not, 43 (71%) cleaned
them with water only.
Prevalence of infections
HBV serology was considered positive (HBVab) - either
acute or chronic active or past cured infection in 29.1%
(95%CI: 25.5-34.7) of IDUs and 8.9% (95%CI: 0.5-17.2)
in nIDUs -including 18 anti-HBc antibodies-only cases
(Table 2). Among IDUs, 3.9% (95%CI: 1.5-6.2) showed
acute or chronic HBV infection (i.e. HBs antigen posi-
tive) where nIDUs showed none. Seroprevalence for
HCVab was 81.3% (95%CI: 76.6-86.0) and 19.1 (95%CI:
7.9-30.3) for nIDUs. HIVab seroroprevalence was 2.5%
(95%CI: 0.3-4.6) in IDUs and 4.8% (95%CI: -1.7-11.3) in
nIDUs. Among IDUs HAVab was 57.1% (95%CI: 50.0-
Table 1 Main characteristics of the study population at inclusion (N = 368)
Parameter (N = 368) Category IDUs N (%) nIDUs N (%)
Gender Male 248/310 (80.0) 47/58 (81.1)
Nationality Luxembourg 183/310 (59.0) 24/58 (41.4)
Portugal 60/310 (19.3) 13/58 (22.4)
Children at charge Yes 54/310 (17.4) 9/58 (15.5)
Life time drug use Heroin 279/279 (100.0) 28/28 (100.0)
Cocaine 280/310 (90.3) 37/58 (63.8)
Cannabis 286/334 (85.6) 48/334 (14.4)
Speedball
(heroin/cocaine combination)
205/310 (84.2) 0/58 (0.0)
Last 6 months IDU Never borrowed used paraphernalia 162/256 (63.3)
Never lend used paraphernalia 161/255 (62.9)
Mostly shared: cups 69/94 (73.4)
Mostly shared: filters 68/94 (72.3)
Mostly shared: syringes 42/94 (44.6)
Last 6 months number of sexual partners (N = 266) None 192/308 (62.3) 32/58 (55.2)
1-9 94/308 (30.5) 26/58 (44.8)
10+ 22/308 (7.1) 0/58 (0)
Imprisonment (N = 366) At least once during the last 10 years 215/308 (69.8) 31/58 (53.4)
Drug consumption in prison (N = 246) Yes 130/215 (60.5) 8/31 (25.8)
Substitution treatment (N = 368) Yes 286/310 (92.3) 19/58 (32.8))
Tattoo or piercing None 87/309 (28.2) 28/58 (48.3)
Tattoo 100/309(32.4) 14/58 (24.1)
Piercing 23/309 (7.4) 9/58 (15.5)
Both 99/309 (32.0) 7/58 (12.1)
Note: Denominators may vary because of missing answers to some questions.
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Page 5 of 1164.1) and 65.9% (95%CI: 51.4-80.4) among nIDUs. No
acute cases of HAV infection (i.e. IgM positive) were
detected. Seroprevalence according to study subpopula-
tions are outlined in Table 2.
Compared to nIDUs, IDUs show higher rates for
HBVab (p = 0.0038) and HBV non- vaccinated status (p
= 0.0001). There is no statistical difference between
IDUs and nIDUs for HBV vaccinated status (p = 0.30),
HAVab (p = 0.31) nor HIVab (p = 0.43), but HCVab is
higher in IDUs (OR: 18.4, 95%CI=[8.4; 40.5]).
Among participants with HCVab, HBVab or HIVab,
96% (218/227), respectively 95% (74/78), and 71% (5/7)
were IDUs.
Co-infections
Among HCV positives, 61.0% (94/154, 95%CI=[53.3;
68.7]) were protected against HBV either by vaccination
(40.3%, 62/154, 95%CI=[32.8; 48.2]) or past infection
(20.8%, 32/154, 95%CI=[15.1; 27.9]). All 7 respondents
with active HBV infection and all 7 HIV-1 positives
were co-infected with HCV.
Covariates of infection: univariate and multivariate
analyses (Table 3 and 4)
In IDUs, HCV (Table 3) and HBV (Table 4) infections
were significantly associated with increasing age and
duration of drug use for heroin, cocaine and speedball.
HCV infection was associated with type of setting
(ITC and PC), substitution treatment history and multi-
ple stays in prison or drug use in prison. None of the
disinfection procedures in prison (water, chlorine, alco-
hol, burned needle, aftershave...) correlated significantly
with HCV. The duration of drug use for cannabis and a
distant date (see Table 4 for duration from last drug
use) of last heroin or amphetamine use was statistically
associated with HCV infection.
HBV infection was significantly associated with
nationality (Portugal) and amphetamine career in IDUs.
In order to assess the risk factors of the different
infections, we entered in the multivariate models vari-
ables with a p-value lower than 0.20 in the univariate
analysis.
For HBV infection in IDUs, multivariate logistic mod-
eling discarded cocaine, heroin and amphetamine
careers. The final model included age (≥25y versus
≤24y: OR = 2.7, 95%CI=[1.2;6.2]), speedball career (≥6y
versus ≤5y: OR = 2.3, 95%CI=[1.1;4.4]) and nationality
(other vs Luxembourg: OR = 2.0, 95%CI=[1.0;4.1]) as
the only significant factors. Age did not appear as a fac-
tor of interaction for speedball career (p = 0.66) and the
model was adjusted to avoid any confusion between
HBV infection and speedball career.
Regarding HCV, the multivariate modeling discarded
cocaine, heroin, speedball and cannabis careers, last her-
oin and amphetamine consumption, substitution treat-
ment, sex partners, imprisonment and drug use in
prison. The final logistic model for HCV infection in
IDUs included age (≥25y vs ≤24y: OR = 4.2, 95%CI=
[2.1;8.6]) and the settings of recruitment (ITR+PC vs
OTC: OR = 2.3, 95%CI=[1.2; 4.6]) as the only significant
factors. Age appeared as a confounding factor for drug
use careers (p = 0.0001).
Self-reporting of infections and immunisations
Comparability and validity of self-reported study results
and respective RELIS data, including sensitivity, sensibil-
ity and agreement analysis have been specifically
addressed in a former research paper [12].
Table 2 Seroprevalence (%)
OTC
N/Ntotal
ITC
N/Ntotal
PC
N/Ntotal
IDUs
N/Ntotal
nIDUs %
N/Ntotal
Active HBV
(HBs ag+)
1.5
2/130
0
0/54
7.0
8/115
3.9
10/254
0
0/45
HBV
(cured or active infection)
Cured HBV
(HBs ab+, HBc ab+)
13.1
17/130
14.8
8/54
23.5
27/115
19.3
49/254
6.7
3/45
Total HBVab * 22.3
29/130
16.7
9/54
34.8
40/115
29.1
74/254
8.9
4/45
HBV vaccination (HBs ab+) 39.2
51/130
57.4
31/54
45.2
52/115
46.1
117/254
37.8
17/45
HBV seropositivity (all types) 61.5
80/130
74.1
40/54
80.0
92/115
75.2
191/254
46.7
21/45
HCV (Elisa +, RIBA +)
HCVab
57.3
75/131
75.4
46/61
86.3
107/124
81.3
218/268
19.1
9/47
HAV (IgG+)
HAVab
54.7
70/128
57.1
24/42
68.3
41/60
57.1
108/189
65.9
27/41
HIV-1
HIVab
1.5
2/130
0
0/49
7.7
5/65
2.5
5/202
4.8
2/42
*Including 18 cases with HBc antibody only.
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concerned, respectively 81 and 59 PDUs out of 360 did
not know about their past 10 years acquired HAV or
HBV immunisation. Respectively 131 and 120 PDUs
self-declared not having been vaccinated against HAV
or HBV.
Of 148 and 181 respondents recalling previous HAV
and HBV vaccination respectively, 22% (33/148) and
Table 3 Covariates of HCV infection in IDUs (univariate analysis)
Parameter Category N per category HCV +
N (%)
OR 95%CI
Age, years (N = 268) 18-24 61 36 (59.0) 1.0
25+ 207 182 (87.9) 5.0 [2.6; 9.8]
Settings (N = 268) OTC 103 74 (71.8) 1
ITC + PC 165 144 (87.3) 2.7 [1.4; 5.0]
Heroin career, years (N = 239) 0-5 51 33 (64.7) 1
6+ 188 166 (88.3) 4.1 [2.0; 8.5]
Cocaine career, years (N = 240) 0-5 89 64 (71.9) 1.0
6+ 151 131 (86.8) 2.6 [1.3; 4.9]
Cannabis, years (N = 248) 0-5 36 24 (66.7) 1.0
6+ 212 182 (85.8) 3.0 [1.4; 6.7]
Speedball career, years (N = 179) 0-5 111 84 (75.7) 1.0
6+ 68 63 (92.6) 4.1 [1.5; 11.1]
Last heroin consumption, m:month (N = 267) 0-1m 155 117 (75.5) 1
2m + 112 100 (89.3) 2.7 [1.3; 5.5]
Last amphetamine consumption y:year (N = 164) 1y 29 18 (62.1) 1
2 y + 135 111 (82.2) 2.8 [1.2; 6.7]
Sex partners, number in last 6 months (N = 267) None 162 139 (85.6) 1
1+ 105 78 (74.3) 0.5 [0.2; 0.9]
Substitution treatment, (N = 268) No 22 13 (59.1) 1.0
Yes 246 205 (83.3) 3.5 [1.4; 8.6]
Imprisoned, times (N = 267) 0-1 197 153 (77.7) 1
2+ 70 64 (91.4) 3.1 [1.2; 7.6]
Drug use in prison, (N = 189) No 75 55 (73.3) 1
Yes 114 103 (90.3) 3.4 [1.5; 7.5]
Table 4 Covariates of HBV infection in IDUs (univariate analysis)
Parameter Category N per category HBV +
N (%)
OR 95%CI
Age, years (N = 254) 18-24 8 12.9 1
25+ 66 34.4 3.5 [1.6; 7.8]
Nationality (N = 254) Other 21 39.6 1
Portugal 20 38.5 2.2 [1.1; 4.3]
Luxembourg 33 22.1 2.3 [1.2; 4.5]
Heroin career, years (N = 227) 0-9 21 22.8 1
10+ 51 37.8 2.1 [1.1; 3.7]
Cocaine career, years (N = 229) 0-5 17 19.8 1
6+ 51 35.7 2.2 [1.2; 4.2]
Speedball career, years (N = 168) 0-5 22 21.4 1
6+ 30 46.2 3.2 [1.6; 6.2]
Amphetamine carreer, years (N = 158) 0-5 22 20.4 1
6+ 19 38.0 2.4 [1.1; 5.0]
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Page 7 of 1120% (36/181) reported one single dose of vaccine, 20%
(29/148) and 16% (29/181) two doses, 47% (69/148) and
55% (99/181) three doses of vaccine; 17 PDUs (11%
HAV, 9% HBV) did not know the number of admini-
strated boosters.
Hepatitis A and/or B immunisations
Protection against HBV was either acquired by past
infection (19.3%, 95%CI=[14.4; 24.2] for IDUs, 6.7% 95%
CI=[-0.6; 14.0] for nIDUs), or by vaccination (46.1%,
95%CI=[40.0; 52.2] for IDUs, 37.8% 95%CI=[23.6; 52.0]
for nIDUs) (Table 2). 26.4% (63/239; 95%CI=[20.8-32.0])
of IDUs, 54.5% (24/44; 95%CI=[39.8-69.2]) of nIDUs
were still susceptible to HBV infection and hence eligi-
ble for HBV immunisation. 43% (81/189; 95%CI=[35.8-
50.0]) of IDUs, 34% (14/41; 95%CI=[20.0-48.6]) of
nIDUs were not immunised against HAV (Table 2).
There was no statistical difference in HBV vaccination
rates between the 3 settings (p = 0.154). However, from
131 PDUs tested in OTC, only 73 (55%) returned to col-
lect their results (Figure 1). Of the latter, 39% (17/43)
received one Twinrix
® dose, 32% (14/43) one Havrix
®
dose and 28% (12/43) one Engerix
® dose. Of the 123
interpretable blood samples, respectively 28 (23%), 30
(24%), 20 (16%) PDUs were potential candidates for vac-
cination against hepatitis A, hepatitis A and B and hepa-
titis B. Fifty-seven percent of PDUs requiring HAV and
HBV immunisation received one Twinrix
® dose, 50%
requiring HAV immunisation received one Havrix
® dose
and 60% requiring HBV immunisation received one
Engerix
® dose. In OTC, 78 (52%) respondents needed
immunisation (HBV and/or HAV) and 43 (55%)
received a first dose of vaccine. No second dose of vac-
cine was administered, as none of the PDUs showed up
for a booster.
Discussion
Our work aims to provide a comprehensive nationwide
insight into selected chronic viral infections in IDUs and
non IDUs. All types of PDU care settings were included
in the study and about 15% of the estimated PDU popu-
lation in Luxembourg was recruited with a low partici-
pation rate of 31% following initial contact. Part of the
explanation may lie within the recruitment in low-
threshold services with PDUs often deferring participa-
tion and not reappearing later.
A comparison between respondents and non-respon-
dents in this hard-to-reach population was not possible
in our study. However, we gathered the most represen-
tative sample of the Luxembourg PDU population
although a selection bias stands with lower participation
rate in outpatients (84%) and higher ones in inpatients
(100%) and prisons (99%). A cross-sectional study con-
ducted in Luxembourg in 1999 also showed a 33.9%
response rate [13]. Other limitations of the study can be
detected in the recruitment method targeting exclusively
the PDUs in contact with ITCs, OTCs or PCs, thereby
not reaching those not in contact with such institutions.
Secondly, the heterogeneity of the types of PDUs (injec-
tors or not) attending the various settings makes the
interpretation of the results somewhat uneasy. Since the
initiation of the project had an action-research design,
the first priority was to reach, test and treat if required
as many PDUs as possible, which implies less selective
recruitment criteria. Also, the questionnaire items did
not allow differentiating between ever- and current
injectors, which would have allowed further in-depth
analysis.
Overall, HCV prevalence was 81.3% in IDUs and
19.1% in non IDUs. Those rates put Luxembourg in the
upper range of HCV prevalence among IDUs in Europe
[1]. Among nIDUs the rate is lower compared to Italy
or Spain [5,6], but remains much higher than the esti-
mated HCV prevalence rate (0.5%-1%) in the general
population [14].
Compared to PCs (86.3%; 95%CI: 80.2-92.3), the pre-
valence of HCV was lower in ITCs (75.4%; 95%CI: 64.6-
86.2) and OTCs (57.3%; 95%CI: 48.8-65.8). There may
be a selection bias in recruitment as outpatients showed
less motivation to participate in the study by postponing
their participation. Also, in prison the access to sterile
material brings IDUs to be more at stake when it comes
to infection risks.
Alike, Belgium [15] reported higher HCV prevalence
rates in imprisoned drug injectors (76%). In the HCV
multivariate analysis, being an IDU older than 25 years
and being in ITC or PC rather than in OTC increased
the risk (OR: 4.2) of HCVab. Consistent with other stu-
dies, each year of injection drug use increases the risk of
contracting HCV by a factor of 1.14, and drug use in
prison generates a risk of 3.16 fold [10,16].
Since no viral load assays were performed in our
study, we were unable to distinguish chronic active from
past resolved HCV infections. Based on literature, we
can estimate however that about 55-85% of seropositive
had indeed an ongoing chronic infection [17]. In addi-
tion, a viral genotype assay might have added valuable
information. A recent study performed in Luxembourg
suggests that IDUs are 4.54 times more likely to be
infected by HCV genotype 3 than other patients, even if
adjusted for age and gender [14]. Genotype 3 has
roughly 80% of chances of sustained response to a stan-
dard 6-month interferon/ribavirin treatment. Preliminary
data now show that a shorter treatment course of only 3
months may have the same cure rate [18]. Therefore,
one might speculate that offering short antiviral treat-
ments to a large number of IDUs with genotype 3
would have the potential to reduce the transmission rate
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reservoir.
In IDUs, HBVab prevalence was 29.1%. Again we
found significantly higher HBVab prevalence in pris-
ons (34.8%;95%CI: 26.1-43.5) compared to other set-
tings. In IDUs, national prevalence rates for HBcAb,
HBsAg and HBsAb are scarce in Europe, ranging
respectively from 0.7%-64%, 2.3%-6.1% and 25%-37%
[19]. Belgium reports 18% HBVab (acute/chronic
infections and cured infections) in IDUs [15]. Our
study shows high HBsAb (65.4%) probably due to a
relatively high HBV vaccination rate in IDUs when
compared to other countries [20,21]. Also, only about
3.9% (95%CI: 1.5-6.3) of IDUs presented active HBV
infection (Antigen HBs positive), leaving little room
for therapeutic interventions. On the other hand, with
only 46% of IDUs (95%CI: 40.0-52.2) protected by vac-
cination and 19.3% (95%CI: 14.5-24.2) having acquired
HBV, there is clearly a need for an improved vaccina-
tion policy at an earlier stage. Among nIDUs, HBVab
prevalence was 8.9%, showing a lower rate than Italy
or Spain (respectively 22.8%, 20.7%) [5,6]. In the HBV
multivariate analysis, increasing age, more than 6
years’ speedball career and non-Luxembourg national-
ity increases the risk of contracting HBV.
The results of the multivariate analysis with increasing
age, more than 6 years’ speedball career and non-Lux-
embourg nationality favouring HBV transmission are
consistent with those of other studies [20,22]. They con-
cur with the need to improve an early stage vaccination
policy and the one to target non-nationals.
Vaccinations for PDUs are recommended in all the
settings wherever feasible and although no difference in
HBV vaccination rates according to different settings
has been observed, awareness should be further raised
among physicians regarding the importance and useful-
ness of HBV vaccination in PDUs.
We found no case of acute HAV infection; however,
41% of PDUs were unprotected against HAV and would
have benefited from immunisation.
The prevalence of HIV among IDUs was 2.5%. Again
the highest prevalence was found in prison (7.7%). In
the European Union, HIV prevalence in IDUs varies
from 1% in the UK to 30% in Spain [23]; Neighbouring
Belgium reports 3% and 4% in prisons among IDUs
[15]. The lower rates for HIV infection compared to
HCV might be explained by lower viral infectivity
[24,25]. Among nIDUs, HIV prevalence was 4.8% show-
ing a higher rate than in Italy (1.6%) and Spain (2.7%)
[5,6]. This rate is also higher than the estimated 0.2%
HIV infection rate in the general population of Luxem-
bourg. Nevertheless, the highest risk of HIV contamina-
tion in Luxembourg, remains through male homosexual
intercourse or heterosexual contacts [26].
Our data shows that co-infections are common. The
univariate analysis in the IDU population associates gen-
der with HBV, age with HBV and HCV, and nationality
with HCV infection. Likewise findings from other stu-
dies [20,21] showed that duration of drug use was signif-
icantly associated with an increase in HBV and HCV
infections (Table 3).
Drug injectors are particularly exposed to infection
risks [27,28] as they are apt to lend or borrow parapher-
nalia. Cups and filters were the most commonly
exchanged objects in our study, even though free of
charge, sterile and ready-to-use kits for drug use are
widely available in the vicinity of the main consumption
spots. Sixty-five percent of drug-injecting study respon-
dents reported discarding their used syringes in syringe
exchange programmes. Worrisome, however, is that syr-
inges are inappropriately eliminated in 23% of the cases
with a syringe/needle separation occurring in 15% and
needles discarded in an inadequate place in 8% of the
cases. These types of behaviour result in increased infec-
tion risks for others. Cleaning or disinfection of used
syringes and needles is predominantly observed in pris-
ons. Yet, 72% use only water (which does not disinfect)
for cleaning, which points out to the fact that appropri-
ate prevention measures were not readily available in
prisons. As lifestyle and consumption habits of PDUs as
well as daily constraints to procure drugs rarely comply
with appointments, the organisation and maintenance of
medical interventions were highly challenging. As long
as the treatment centres’ employees and the field inves-
tigator who had established close contacts with the par-
ticipants, reminded them of their appointments, about
half (54.6%) of the tested PDUs saw the physicians and
received immunisations where appropriate. After the 8-
month inclusion period, only the physicians were active
in the field in order to complete the immunisation pro-
grammes. Although the system was meticulously
planned, not one additional follow-up was obtained
under these conditions. One way of improvement might
be rapid, point-of-care tests providing results in a few
minutes and allowing immediate advice and immunisa-
tion if appropriate. However, even if completing a vacci-
nation scheme was the ultimate goal, one has to bear in
mind the concept « One dose is better than no dose »
[29], which suggests that there is a protective effect even
from uncompleted schemes.
Conclusions
In conclusion, our findings confirm that the prevalence
of chronic viral infections and especially HCV is high
among IDUs in Luxembourg. Also, the prevalence
among nIDUs is noticeable for HBV. Therefore low-
threshold opportunities for immediate testing, informa-
tion on prevention, access to prevention material,
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Page 9 of 11immunisation and treatment if appropriate should be
improved among PDUs. A syringe distribution pro-
gramme for IDUs in prisons is highly suggested and has
been in force in Luxembourg since the summer of 2005.
Awareness should be further raised among physicians
regarding the importance and usefulness of HBV/HAV
vaccination in PDUs at the earliest stage of PDU. Tack-
ling the problem of chronic viral infections in PDU is
difficult, especially when it comes to gaining adherence
to screening and immunisation schemes as shown in
our study. In order to evaluate future trends in viral
infections and effects of prevention programmes, the
implementation of a continuous surveillance system for
chronic viral infections in the PDU population should
be considered [30,31].
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